Dasmahapatra Upala, Kumar Chitluri Kiran, Das Soumyadip, Subramanian Prathima Thimma, Murali Poornimaa, Isaac Arnold Emerson, Ramanathan Karuppasamy, Mm Balamurali, Chanda Kaushik
Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Front Chem. 2022 Sep 30;10:991369. doi: 10.3389/fchem.2022.991369. eCollection 2022.
With an alarming increase in the number of cancer patients and a variety of tumors, it is high time for intensive investigation on more efficient and potent anti-tumor agents. Though numerous agents have enriched the literature, still there exist challenges, with the availability of different targets and possible cross-reactivity. Herein we have chosen the phosphoinositide 3-kinase (PI3K) as the target of interest and investigated the potential of pyrido fused imidazo[4,5-]quinoline derivatives to bind strongly to the active site, thereby inhibiting the progression of various types of tumors. The AutoDock, Glide and the Prime-MM/GBSA analysis are used to execute the molecular docking investigation and validation for the designed compounds. The anti-tumor property evaluations were carried out by using PASS algorithm. Based on the GLIDE score, the binding affinity of the designed molecules towards the target PI3K was evaluated. The energetics associated with static interactions revealed as the most potential candidate and the dynamic investigations including RMSD, RMSF, Rg, SASA and hydrogen bonding also supported the same through relative stabilization induced through ligand interactions. Subsequently, the binding free energy of the Wortmannin and complex calculated using MM-PBSA analysis. Further evaluations with PASS prediction algorithm also supported the above results. The studies reveal that there is evidence for considering appropriate pyrido fused imidazo[4,5-]quinoline compounds as potential anti-tumor agents.
随着癌症患者数量和肿瘤种类的惊人增加,对更高效、更有效的抗肿瘤药物进行深入研究迫在眉睫。尽管众多药物丰富了文献,但由于存在不同的靶点和可能的交叉反应性,仍然存在挑战。在此,我们选择磷酸肌醇3激酶(PI3K)作为感兴趣的靶点,并研究吡啶稠合咪唑并[4,5-]喹啉衍生物与活性位点强烈结合的潜力,从而抑制各种类型肿瘤的进展。使用AutoDock、Glide和Prime-MM/GBSA分析对设计的化合物进行分子对接研究和验证。通过PASS算法进行抗肿瘤性能评估。基于GLIDE评分,评估设计分子对靶点PI3K的结合亲和力。与静态相互作用相关的能量学表明其为最具潜力的候选物,包括RMSD、RMSF、Rg、SASA和氢键的动态研究也通过配体相互作用诱导的相对稳定性支持了这一点。随后,使用MM-PBSA分析计算渥曼青霉素与复合物的结合自由能。使用PASS预测算法的进一步评估也支持了上述结果。研究表明,有证据表明可将合适的吡啶稠合咪唑并[4,5-]喹啉化合物视为潜在的抗肿瘤药物。